Motoric Cognitive Risk Syndrome: Predictor of Dementia and Age-Related Negative Outcomes
Jagadish K. Chhetri
Piu Chan2
Matteo Cesari- 1Gérontopôle, Department of Geriatrics, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
- 2Department of Neurobiology, Geriatrics, and Neurology, Beijing Institute of Geriatrics, Xuanwu Hospital of Capital Medical University, Beijing, China
- 3INSERM UMR 1027, University of Toulouse III Paul Sabatier, Toulouse, France
Cognitive disorders represent a leading cause of disability in the aging population, of which dementia has the highest global burden. Early signs of dementia such as slow gait and memory complaints are known to present well before the overt manifestation of the disease. Motoric cognitive risk (MCR) syndrome characterized by the simultaneous presence of gait disturbances and memory complaints in older subjects has been proposed to study the close interactions between the physical and cognitive domains as well as a possible approach to identify individuals at increased risk of dementia. In addition, studies have shown MCR as a predictor of other negative outcomes in older adults, including disability, falls and death. However, the concept of MCR is still in its early stage and approach to the syndrome is still not well established. This review aims to put together the various aspects of MCR syndrome including its pathophysiology, diagnosis, epidemiology, and relationship with other geriatric conditions.
Introduction
Older adults are known to have decreased functional capacity (e.g., sensory, cognitive, physical), which makes them vulnerable to adverse events such as disability, dependency, falls, or even death (1–5). Poor mobility of lower limbs with aging is one of the most commonly presented form of physical limitation in older individuals (6). Several studies have shown gait speed to predict major health-related events in older adults (6–8). Similarly, decline in memory is another common form of cognitive limitation associated with increase in age, which might potentially progress to dementia (9, 10). Furthermore, evidences from past studies have shown coexistence of cognitive decline and gait abnormality (that might be of musculoskeletal or neuro-sensory-motor etiology) to be a common condition in older adults (3, 11, 12). Besides, these functional limitations are known to be the major causes of disability and dependency in older adults (7, 11, 13, 14).
Growing body of evidence suggests that simultaneous presence of cognitive complaints with reduced gait speed may indicate early signs of dementia (presenting decades before actual presentation of cognitive impairment) (15–20). Unfortunately, very little is known about how the actual interaction between the cognitive and physical domain (such as which domain triggers the other, or time-point of initiation) occurs with the phenomenon of aging. Intuitively, an entity that captures both physical and cognitive functional status of an aging individual could reflect a more implicit functional status of the individual. Moreover, such entity would aid researchers to better understand the interaction between cognition and physical domains in aging individuals who are at high-risk of dementia and other geriatric disorders.
In this review, we discuss on a novel concept described as motoric cognitive risk (MCR) syndrome that captures the state of concomitant presence of gait disturbances and cognitive decline in older adults (20). Studies have shown MCR to be an effective tool in predicting various geriatric conditions such as dementia (19), falls (21), disability (22), and mortality (1).
Gait and Cognition in Older Adults
Gait: Walking is a very common activity of daily living, which at a glance appears to be an entirely unsophisticated automated motor task. However, maintaining of normal gait is a much complex process requiring intact multisystem (nervous, sensory, musculoskeletal, cardiorespiratory) function and coordination (3, 16, 17). With increase in age, the parameters of gait (velocity, stride length, swing time) are affected as a result of disturbances in either of the musculoskeletal functions, locomotor function, balance, postural reflexes, sensory function and sensorimotor integration, and cardiorespiratory functions (23), resulting abnormal gait.
At present, gait speed or gait velocity has increasingly been implemented in clinical settings to evaluate functional status in older subjects and even to predict adverse events (1, 18, 21, 22, 24). In addition, slow gait speed is thought to be a sensitive marker of cognitive decline with aging (18, 25–28). However, the methods and cut-off values for assessment of gait in older subjects is known to vary widely. Moreover, every cut-point might be arbitrary because the relationship between gait speed and risk of negative outcomes follows a linear trend. Nevertheless, gait speed less than 0.8 m/s over a 4-m track is one of the most commonly used cut-points to assess gait speed in older subjects (29). The cut-point has been suggested to predict adverse events in older adults by the International Academy on Nutrition and Aging task force (29) and recommended for further clinical investigation by the European consensus on sarcopenia (30). On the other hand, the concept of “dis-mobility” describes a much slower gait speed of less than 0.6 m/s to be a relevant cut-point suitable for improving clinical care, research, and regulatory approval of treatments to improve mobility in older adults (31). Gait abnormalities have been identified from early neurological studies and subclassified as unsteady, ataxic, frontal, parkinsonian, neuropathic, hemiparetic, or spastic (23, 32) depending upon the nature of the disturbances that should be properly identified by physicians while assessing older adults.
Cognition: Cognition relates to the functioning processes of the brain, which tends to change with age (33). Cognitive functions such as attention, intelligence, memory, processing speed, and executive function are known to decline with increase in age with varying degree between individuals (34), which could affect the overall functioning of an individual including gait. This alteration in cognition with aging has been associated primarily with decline in brain gray and white matter volume (35), brain hippocampus volume (36), and deposition of protein beta-amyloid in brain [a primary marker of Alzheimer’s disease (AD)] (37). Factors such as cardiovascular diseases (and associated risk factors), genetics, low level of education and depression have been identified as major contributing factors for cognitive decline (38), which could simultaneously influence the overall physical functioning. Assessment scales such as clinical dementia rating (CDR) (39), Mini-Mental State Examination (40), and other forms of dementia screening questionnaire have been widely used to assess overall cognitive status of older adults.
Link between Gait and Cognition
As discussed before, gait is a sequel of multifactorial and multisystem coordination, but primarily the result of neuromuscular interaction capacity of an individual. Anatomically speaking, brain frontal subcortical circuits predominantly mediate gait (41). Executive function (3, 42) and attention (42–44) have been suggested to be the primary cognitive processes associated. However, the frontal lobe itself is vulnerable to age-related changes (42), which could alter gait speed and cognition in older adults. In addition, declination or improvement in executive function and attention over time was found to effect gait progression (speed) in older adults (17, 27, 42). Increased brain subcortical white matter hyper-intensities (leukoaraiosis) (45) and decrease in cerebellar gray matter volume (46) and hippocampal volumes (47) were found to be associated with reduced gait speed. This overlap between the brain areas controlling gait and cognition explains the relationship between slow gait and dementia pathologies. Furthermore, a dual-task methodology termed as “walking while talking” was developed for making the gait speed assessment more challenging and included the evaluation of cognition (48–50). The participant’s change in motor performance during dual-task was observed suggesting requirement of additional cognitive resources to maintain multisystem coordination, which might be difficult to achieve for older individuals with cognitive limitation, leading to detrimental effects such as falls. Besides, a recent meta-analysis has shown evidences of brain structure to be associated with muscle structure and function (51), showing the consequential association between these domains, which could alter gait function.
Factors Associated
Physical limitations and cognitive decline have been suggested to present bidirectional relationship (3, 17, 52). These conditions most likely share the common risk factors and pathways such as chronic inflammation, hormonal pathways, lifestyle factors, and even genetic pathway (11, 53–57).
Low-grade chronic inflammation or “inflamm-aging” might be the primary biological pathway shared by gait and cognition in older individuals (58–62). Atherosclerosis, a chronic inflammatory condition in older adults is known to promote cardiovascular dysfunction that could increase functional loss (both cognitive and physical) in aged individuals (61, 63, 64). Furthermore, chronic inflammation is found to directly impact the central nervous system (e.g., neurofibrillary tangles, amyloid plaques) of older adults (65–67) and promote cardiovascular risk factors (59, 61, 68, 69). Increased serum C-reactive protein, interleukin-6, and plasma tumor necrosis factor-α are the inflammatory markers associated with decrease in total brain volume (58, 65, 70, 71) that could affect cognition and gait simultaneously.
Cardiovascular risk factors (e.g., hypertension, diabetes, hyperlipidemia) are known to enhance incidences of cerebral ischemia affecting the periventricular white matter (64, 72, 73). As explained before, brain white matter plays an important role in the control of gait and cognitive processing and responsible for executive function (45, 64, 73). Similarly, other conditions such as neurodegeneration (e.g., in Parkinson’s disease) in older adults is well known to impact both cognition and motoric functions (74).
Needless to elaborate, nutritional factor is a key component to influence physical function in humans. Besides, abundant studies have shown that the deficiency of nutritional factors may affect both cognition and physical functions in older adults (53, 54, 75, 76). Similarly, physical exercise is another factor that is well known to influence both cognition and physical limitations in older adults (77–80). Functional decline in older adults is also known to be influenced by hormonal alteration (such as downregulation of insulin-like growth factor) with aging (81) and genetic factors such as apolipoprotein-E4 (APOE-4 genotype) (55, 56).
MCR Syndrome
Motoric cognitive risk syndrome is defined as a condition characterized by slowness of gait in the presence of subjective cognitive complaint in older adults without any form of dementia or mobility disability (1, 18–22). The theory that slowness of gait coexisting with cognitive decline might be an early sign of dementia, which has been used in this novel entity, potentially resembling a pre-dementia syndrome (18, 19, 22) (Figure 1).
Figure 1. Diagrammatic presentation of motoric cognitive risk syndrome.
The following four criteria have been proposed to be met for the diagnosis of MCR (although the use of scales was not uniform in prior studies—Table 1) (1, 18–22): (1) presence of subjective cognitive complaints, assessed using standardized questionnaire (e.g., CDR, GDS, or AD screening questionnaire), (2) presence of slow gait: defined as velocity one SD or more below age- and sex-appropriate mean values, (3) preserved mobility, and (4) absence of dementia.
Table 1. Frequent methods implemented to diagnose motoric cognitive risk syndrome.
Motoric cognitive risk was found to have a prevalence ranging from 2 to 18% (83, 84, 86, 87). A multi-country (17 countries worldwide) study showed an overall pooled prevalence of almost 10% (83). These studies have shown MCR to have a higher prevalence and incidence in older age irrespective of gender. Based on the current availability of data, cross country comparison lowest prevalence of 2% was found in the United Kingdom and Australian cohort, and higher prevalence of 15% in Indian cohort and the highest prevalence of 16–18% was found in French population (83, 84, 86, 87).
Factors such as stroke, diabetes, obesity, depression, and sedentariness have been found to be associated with high risk of MCR in older adults (85, 86). Additional studies in much diverse sociodemographic settings are required for confirming the global burden of the condition and accordingly identify the associated risk factors.
MCR Syndrome As a Predictor Of
Dementia
Relevant links between cognition and gait have been established earlier. Older adults with cognitive impairment are known to have slower pace (26). Verghese and colleagues in the early 2000 implicated that presence of neurological gait in older adults could predict the risk of dementia (18). However, predictive capacity of MCR with regards to subtypes of dementia was found to be different according to study cohort. In the Einstein Aging Study, MCR was found to be highly prevalent with age and was a strong predictor of vascular dementia (VaD) (19). Older subjects with MCR were found to be at more than 3-folds risk [hazard ratio (HR) = 3.27] of future dementia (except AD) and particularly over 12-folds risk (HR = 12.81) of VaD. However, slow gait was the only gait parameter used which might have decreased the predictive validity of MCR.
In another multi-country study, MCR predicted dementia in multiple cohorts as well as pooled sample, with risks ranging from 1.79- to 2.10-folds (83). Interestingly, MCR was found to be associated with increased risk of AD in two cohorts of the study with 2.21- and 1.97-folds risk, while very few cases of VaD dementia were present in the cohort. However, the cohorts were limited to only 17 countries; therefore, the predictive strength cannot represent for all at-risk subjects [as the primary criteria of MCR cognitive complaint and slow gait can vary demographically (88)], and not to forget the major risk factors that have varied demographic distribution. Additionally, information on APOE-4 genotype [that is known to impact progression of dementia (55)] was not included on this multi-country study, which could have further strengthened the validity of MCR dementia predictive capacity.
Interestingly, a retrospective study in Japanese older population has further elaborated the relation between MCR and dementia (89). The authors have reported the rate of conversion to dementia was 119.8/1,000 persons per year in MCR population, while the non-MCR group was 102.5/1,000 persons per year (OR = 1.38). Slow gait and low scores in executive function tests were found to be predictive of higher rate of conversion to dementia.
Falls
A very high frequency of falls (32–42% per year) in older people over 70 years has been estimated (90), which could result in many detrimental effects including disability or death (91, 92). As discussed earlier, maintaining a normal well-balanced gait requires an efficient integration of motoric, cognitive, and psychological function (3, 5, 16, 17) and the inability to maintain a normal gait could result in falls. Impairment in cognitive domains such as executive function, attention, processing speed, and memory is known to increase the risks of falls. However, age-related loss in white matter integrity is thought to be one of the key mechanisms affecting the cognitive domain responsible (57, 93). Thus, from our explanations earlier, we could expect MCR to be a sensitive predictor of falls in older adults.
A study by Callisaya and colleagues with a combined five large cohorts across three countries found subjects with MCR to be at 44% at high risk of falls in pooled analysis (21). The study showed that slow gait [risk ratio (RR) = 1.30] and memory complaints (RR = 1.25) were also individually associated with increased risk of falls. Whereas, exclusion of MCR case in the study showed a slight decreased association of slow gait (RR = 1.25) and memory complaints (RR = 1.17) with falls. Even after adjustments for previous falls, MCR was significantly associated with falls (RR = 1.29) and multiple falls (RR = 1.37) in pooled analysis. No doubt, the results from the study show MCR to be an effective risk screening tool for falls, as the associations observed were relatively stronger. However, due to different criteria/procedures used for diagnosis of MCR and falls, heterogeneity was present in the pooled analysis.
Disability
Very few studies discussing the associations of MCR and disability are available. However, it can be expected that older individuals with coexisting memory decline and physical limitation are likely to be disabled (or lose independency) if not provided with proper medical attention at an early phase. A very recent study involving 4,235 Japanese older adults (mean age of 72 years) has suggested MCR to be able to predict risk for disability (HR = 1.69) (22). The diagnostic criterion for disability was here regarded as certification by long-term care insurance. Nevertheless, the study has provided some perspectives for future studies, which could implement a more clinical diagnostic method for disability. The findings from this study have verified that individuals with slow gait and cognitive impairment are at high risk of disability, and more studies are demanded to confirm the findings.
Death
As discussed earlier, maintaining intact gait is a complex process requiring multisystem/multifunction coordination, therefore could represent a person’s holistic level of healthiness. Studies have shown gait speed to be a very strong predictor of survival (8) and cognitive impairment is also known to predict mortality (94). MCR involves both cognition and gait, has a high prevalence (83, 84, 86, 87), is known to predict falls (21), dementia (18, 19, 22), and therefore could be a more sensitive predictor of death.
A study by Ayers and Verghese (1) including 11,867 participants from three different cohorts found MCR at baseline was associated with increased overall mortality (HR = 1.69) and increased risk of death even after adjustments for gait and memory test scores (HR = 1.19). The results from the study showed MCR to be a predictor of 2 years mortality, but MCR death predictive capacity in dementia subjects was found to be insignificant. However, it should be noted that the included cohorts of the study were from Europe and United states; therefore, results from the study cannot be interpreted as the global mortality predictive capacity of MCR. Moreover, the study population were community dwelling older adults, who tend to be in better shape compared to the institutionalized. As the study was a population-based study cases of diagnosed dementia could have been underreported, which could have underestimated the prediction of mortality in diagnosed dementia subjects.
The Paradox of MCR Syndrome
An existing paradox of the MCR is whether to consider it as a condition to treat or a mere matter for research purposes? As discussed above, MCR was found to predict wide spectrum of abnormalities in older adults (1, 19, 21, 22) and has a high prevalence ranging up to 18% (83, 84, 86, 87). For these reasons, attention on further approach of this novel syndrome is necessary. Although past studies have stressed on the versatility of diagnosing MCR (20), the clinical approach of the syndrome is vague. In the clinical scenario, we could only attempt to investigate the underlying pathologies of the condition and treat them in traditional manner (that requires various medical tests, despite of considering MCR easy to diagnose), which might require more resources and perhaps even create additional confusion in clinicians. On the other hand, if we consider it as screening tool to identify the at-risk population for the abnormalities it can predict, various effective tools for the purpose already exist (with prior extensive studies involving different sociodemographic population settings). In this context, MCR might be more suitable as a research entity to exclusively investigate the interactions between the physical and cognitive domains (which is not well understood yet) in older population with high risk of conditions that can be predicted by it. Furthermore, these understandings could enable us to design preventive strategies to ameliorate many geriatric conditions including dementia.
Conclusion
In summary, with population aging, the burden of cognitive disorders such as dementia is still escalating. Frequent coexistence of physical limitation and cognitive decline occur in aging individuals, leading to many detrimental effects. MCR includes the evaluation of potential precursors of physical limitation (i.e., gait speed) and cognitive decline (i.e., subjective memory complaints) in order to predict multiple age-related conditions including dementia. Future perspective of MCR might be as a research tool to particularly investigate the relationship between physical and cognitive domain in older adults, further elucidate our understanding of the interaction between these two domains. Results from such studies could facilitate in designing more effective preventive intervention strategies against dementia and other age-related negative outcomes.
Author Contributions
JC: manuscript preparation and drafting; all authors: conception and design, critical revision, and approvement for final version.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
The reviewer AC and handling editor declared their shared affiliation.
References
1. Ayers E, Verghese J. Motoric cognitive risk syndrome and risk of mortality in older adults. Alzheimers Dement (2016) 12:556–64. doi:10.1016/j.jalz.2015.08.167
2. Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. Lancet Lond Engl (2013) 381:752–62. doi:10.1016/S0140-6736(12)62167-9
3. Cohen JA, Verghese J, Zwerling JL. Cognition and gait in older people. Maturitas (2016) 93:73–7. doi:10.1016/j.maturitas.2016.05.005
4. Rantanen T. Muscle strength, disability and mortality. Scand J Med Sci Sports (2003) 13:3–8. doi:10.1034/j.1600-0838.2003.00298.x
5. Rosso AL, Studenski SA, Chen WG, Aizenstein HJ, Alexander NB, Bennett DA, et al. Aging, the central nervous system, and mobility. J Gerontol A Biol Sci Med Sci (2013) 68:1379–86. doi:10.1093/gerona/glt089
6. Guralnik JM, Ferrucci L, Simonsick EM, Salive ME, Wallace RB. Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability. N Engl J Med (1995) 332:556–61. doi:10.1056/NEJM199503023320902
7. Perera S, Patel KV, Rosano C, Rubin SM, Satterfield S, Harris T, et al. Gait speed predicts incident disability: a pooled analysis. J Gerontol A Biol Sci Med Sci (2016) 71:63–71. doi:10.1093/gerona/glv126
8. Studenski S, Perera S, Patel K, Rosano C, Faulkner K, Inzitari M, et al. Gait speed and survival in older adults. JAMA (2011) 305:50–8. doi:10.1001/jama.2010.1923
9. Jonker C, Geerlings MI, Schmand B. Are memory complaints predictive for dementia? A review of clinical and population-based studies. Int J Geriatr Psychiatry (2000) 15:983–91. doi:10.1002/1099-1166(200011)15:11<983::AID-GPS238>3.0.CO;2-5
10. Reid LM, Maclullich AMJ. Subjective memory complaints and cognitive impairment in older people. Dement Geriatr Cogn Disord (2006) 22:471–85. doi:10.1159/000096295
11. Boyle PA, Buchman AS, Wilson RS, Leurgans SE, Bennett DA. Physical frailty is associated with incident mild cognitive impairment in community-based older persons. J Am Geriatr Soc (2010) 58:248–55. doi:10.1111/j.1532-5415.2009.02671.x
12. Robertson DA, Savva GM, Kenny RA. Frailty and cognitive impairment – a review of the evidence and causal mechanisms. Ageing Res Rev (2013) 12:840–51. doi:10.1016/j.arr.2013.06.004
13. Lindbergh CA, Dishman RK, Miller LS. Functional disability in mild cognitive impairment: a systematic review and meta-analysis. Neuropsychol Rev (2016) 26:129–59. doi:10.1007/s11065-016-9321-5
14. Artero S, Touchon J, Ritchie K. Disability and mild cognitive impairment: a longitudinal population-based study. Int J Geriatr Psychiatry (2001) 16:1092–7. doi:10.1002/gps.477
15. Prince M, Bryce R, Ferri C. World Alzheimer Report 2011: The Benefits of Early Diagnosis and Intervention. Alzheimer’s Disease International (2011). Available from: https://www.alz.co.uk/research/world-report-2011
16. de Borges SM, Radanovic M, Forlenza OV. Correlation between functional mobility and cognitive performance in older adults with cognitive impairment. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn (2016):1–10. doi:10.1080/13825585.2016.1258035
17. Martin KL, Blizzard L, Wood AG, Srikanth V, Thomson R, Sanders LM, et al. Cognitive function, gait, and gait variability in older people: a population-based study. J Gerontol A Biol Sci Med Sci (2013) 68:726–32. doi:10.1093/gerona/gls224
18. Verghese J, Lipton RB, Hall CB, Kuslansky G, Katz MJ, Buschke H. Abnormality of gait as a predictor of non-Alzheimer’s dementia. N Engl J Med (2002) 347:1761–8. doi:10.1056/NEJMoa020441
19. Verghese J, Wang C, Lipton RB, Holtzer R. Motoric cognitive risk syndrome and the risk of dementia. J Gerontol A Biol Sci Med Sci (2013) 68:412–8. doi:10.1093/gerona/gls191
20. Ayers E, Verghese J. Diagnosing motoric cognitive risk syndrome to predict progression to dementia. Neurodegener Dis Manag (2014) 4:339–42. doi:10.2217/nmt.14.39
21. Callisaya ML, Ayers E, Barzilai N, Ferrucci L, Guralnik JM, Lipton RB, et al. Motoric cognitive risk syndrome and falls risk: a multi-center study. J Alzheimers Dis (2016) 53:1043–52. doi:10.3233/JAD-160230
22. Doi T, Shimada H, Makizako H, Tsutsumimoto K, Verghese J, Suzuki T. Motoric cognitive risk syndrome: association with incident dementia and disability. J Alzheimers Dis (2017) 59:77–84. doi:10.3233/JAD-170195
23. Pirker W, Katzenschlager R. Gait disorders in adults and the elderly: a clinical guide. Wien Klin Wochenschr (2017) 129:81–95. doi:10.1007/s00508-016-1096-4
24. Toba K. [The guideline for comprehensive geriatric assessment]. Nihon Ronen Igakkai Zasshi Jpn J Geriatr (2005) 42:177–80. doi:10.3143/geriatrics.42.177
25. Dumurgier J, Artaud F, Touraine C, Rouaud O, Tavernier B, Dufouil C, et al. Gait speed and decline in gait speed as predictors of incident dementia. J Gerontol A Biol Sci Med Sci (2017) 72:655–61. doi:10.1093/gerona/glw110
26. Hooghiemstra AM, Ramakers IHGB, Sistermans N, Pijnenburg YAL, Aalten P, Hamel REG, et al. Gait speed and grip strength reflect cognitive impairment and are modestly related to incident cognitive decline in memory clinic patients with subjective cognitive decline and mild cognitive impairment: findings from the 4c study. J Gerontol A Biol Sci Med Sci (2017) 72:846–54. doi:10.1093/gerona/glx003
27. Callisaya ML, Blizzard CL, Wood AG, Thrift AG, Wardill T, Srikanth VK. Longitudinal relationships between cognitive decline and gait slowing: the tasmanian study of cognition and gait. J Gerontol A Biol Sci Med Sci (2015) 70:1226–32. doi:10.1093/gerona/glv066
28. Mielke MM, Roberts RO, Savica R, Cha R, Drubach DI, Christianson T, et al. Assessing the temporal relationship between cognition and gait: slow gait predicts cognitive decline in the Mayo Clinic Study of Aging. J Gerontol A Biol Sci Med Sci (2013) 68:929–37. doi:10.1093/gerona/gls256
29. Abellan van Kan G, Rolland Y, Andrieu S, Bauer J, Beauchet O, Bonnefoy M, et al. Gait speed at usual pace as a predictor of adverse outcomes in community-dwelling older people an International Academy on Nutrition and Aging (IANA) Task Force. J Nutr Health Aging (2009) 13:881–9. doi:10.1007/s12603-009-0246-z
30. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. Age Ageing (2010) 39:412–23. doi:10.1093/ageing/afq034
31. Cummings SR, Studenski S, Ferrucci L. A diagnosis of dismobility – giving mobility clinical visibility: a Mobility Working Group recommendation. JAMA (2014) 311:2061–2. doi:10.1001/jama.2014.3033
32. Sudarsky L. Geriatrics: gait disorders in the elderly. N Engl J Med (1990) 322:1441–6. doi:10.1056/NEJM199005173222007
33. Salthouse T. Consequences of age-related cognitive declines. Annu Rev Psychol (2012) 63:201–26. doi:10.1146/annurev-psych-120710-100328
34. Wisdom NM, Mignogna J, Collins RL. Variability in Wechsler Adult Intelligence Scale-IV subtest performance across age. Arch Clin Neuropsychol (2012) 27:389–97. doi:10.1093/arclin/acs041
35. Salat DH, Kaye JA, Janowsky JS. Prefrontal gray and white matter volumes in healthy aging and Alzheimer disease. Arch Neurol (1999) 56:338–44. doi:10.1001/archneur.56.3.338
36. Raz N, Rodrigue KM, Head D, Kennedy KM, Acker JD. Differential aging of the medial temporal lobe: a study of a five-year change. Neurology (2004) 62:433–8. doi:10.1212/01.WNL.0000106466.09835.46
37. Rodrigue KM, Kennedy KM, Park DC. Beta-amyloid deposition and the aging brain. Neuropsychol Rev (2009) 19:436–50. doi:10.1007/s11065-009-9118-x
38. Baumgart M, Snyder HM, Carrillo MC, Fazio S, Kim H, Johns H. Summary of the evidence on modifiable risk factors for cognitive decline and dementia: a population-based perspective. Alzheimers Dement J (2015) 11:718–26. doi:10.1016/j.jalz.2015.05.016
39. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry (1982) 140:566–72. doi:10.1192/bjp.140.6.566
40. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res (1975) 12:189–98. doi:10.1016/0022-3956(75)90026-6
41. Holtzer R, Verghese J, Xue X, Lipton RB. Cognitive processes related to gait velocity: results from the Einstein Aging Study. Neuropsychology (2006) 20:215–23. doi:10.1037/0894-4105.20.2.215
42. Yogev-Seligmann G, Hausdorff JM, Giladi N. The role of executive function and attention in gait. Mov Disord (2008) 23:329–42; quiz 472. doi:10.1002/mds.21720
43. Parihar R, Mahoney JR, Verghese J. Relationship of gait and cognition in the elderly. Curr Transl Geriatr Exp Gerontol Rep (2013) 2. doi:10.1007/s13670-013-0052-7
44. Chen HC, Schultz AB, Ashton-Miller JA, Giordani B, Alexander NB, Guire KE. Stepping over obstacles: dividing attention impairs performance of old more than young adults. J Gerontol A Biol Sci Med Sci (1996) 51:M116–22. doi:10.1093/gerona/51A.3.M116
45. Smith EE, O’Donnell M, Dagenais G, Lear SA, Wielgosz A, Sharma M, et al. Early cerebral small vessel disease and brain volume, cognition, and gait. Ann Neurol (2015) 77:251–61. doi:10.1002/ana.24320
46. Nadkarni NK, Nunley KA, Aizenstein H, Harris TB, Yaffe K, Satterfield S, et al. Association between cerebellar gray matter volumes, gait speed, and information-processing ability in older adults enrolled in the Health ABC study. J Gerontol A Biol Sci Med Sci (2014) 69:996–1003. doi:10.1093/gerona/glt151
47. Ezzati A, Katz MJ, Lipton ML, Lipton RB, Verghese J. The association of brain structure with gait velocity in older adults: a quantitative volumetric analysis of brain MRI. Neuroradiology (2015) 57:851–61. doi:10.1007/s00234-015-1536-2
48. Beurskens R, Bock O. Age-related deficits of dual-task walking: a review. Neural Plast (2012) 2012:131608. doi:10.1155/2012/131608
49. Holtzer R, Mahoney JR, Izzetoglu M, Izzetoglu K, Onaral B, Verghese J. fNIRS study of walking and walking while talking in young and old individuals. J Gerontol A Biol Sci Med Sci (2011) 66:879–87. doi:10.1093/gerona/glr068
50. Camicioli R, Howieson D, Lehman S, Kaye J. Talking while walking: the effect of a dual task in aging and Alzheimer’s disease. Neurology (1997) 48:955–8. doi:10.1212/WNL.48.4.955
51. Kilgour AHM, Todd OM, Starr JM. A systematic review of the evidence that brain structure is related to muscle structure and their relationship to brain and muscle function in humans over the lifecourse. BMC Geriatr (2014) 14:85. doi:10.1186/1471-2318-14-85
52. Morley JE, Morris JC, Berg-Weger M, Borson S, Carpenter BD, Del Campo N, et al. Brain health: the importance of recognizing cognitive impairment: an IAGG consensus conference. J Am Med Dir Assoc (2015) 16:731–9. doi:10.1016/j.jamda.2015.06.017
53. Atkinson HH, Rosano C, Simonsick EM, Williamson JD, Davis C, Ambrosius WT, et al. Cognitive function, gait speed decline, and comorbidities: the health, aging and body composition study. J Gerontol A Biol Sci Med Sci (2007) 62:844–50. doi:10.1093/gerona/62.8.844
54. Vandewoude M, Barberger-Gateau P, Cederholm T, Mecocci P, Salvà A, Sergi G, et al. Healthy brain ageing and cognition: nutritional factors. Eur Geriatr Med (2016) 7:77–85. doi:10.1016/j.eurger.2015.12.005
55. El Haj M, Antoine P, Amouyel P, Lambert J-C, Pasquier F, Kapogiannis D. Apolipoprotein E (APOE) ε4 and episodic memory decline in Alzheimer’s disease: a review. Ageing Res Rev (2016) 27:15–22. doi:10.1016/j.arr.2016.02.002
56. Doi T, Shimada H, Makizako H, Tsutsumimoto K, Uemura K, Suzuki T. Apolipoprotein E genotype and physical function among older people with mild cognitive impairment. Geriatr Gerontol Int (2015) 15:422–7. doi:10.1111/ggi.12291
57. Liu Y, Chan JSY, Yan JH. Neuropsychological mechanisms of falls in older adults. Front Aging Neurosci (2014) 6:64. doi:10.3389/fnagi.2014.00064
58. Bruunsgaard H, Pedersen M, Pedersen BK. Aging and proinflammatory cytokines. Curr Opin Hematol (2001) 8:131–6. doi:10.1097/00062752-200105000-00001
59. Franceschi C, Garagnani P, Vitale G, Capri M, Salvioli S. Inflammaging and “Garb-aging”. Trends Endocrinol Metab (2017) 28:199–212. doi:10.1016/j.tem.2016.09.005
60. Franceschi C, Bonafè M, Valensin S, Olivieri F, De Luca M, Ottaviani E, et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci (2000) 908:244–54. doi:10.1111/j.1749-6632.2000.tb06651.x
61. Theuma P, Fonseca VA. Inflammation and emerging risk factors in diabetes mellitus and atherosclerosis. Curr Diab Rep (2003) 3:248–54. doi:10.1007/s11892-003-0072-3
62. Fougère B, Boulanger E, Nourhashémi F, Guyonnet S, Cesari M. Chronic inflammation: accelerator of biological aging. J Gerontol A Biol Sci Med Sci (2017) 72:1218–25. doi:10.1093/gerona/glw240
63. Taleb S. Inflammation in atherosclerosis. Arch Cardiovasc Dis (2016) 109:708–15. doi:10.1016/j.acvd.2016.04.002
64. Santos CY, Snyder PJ, Wu W-C, Zhang M, Echeverria A, Alber J. Pathophysiologic relationship between Alzheimer’s disease, cerebrovascular disease, and cardiovascular risk: a review and synthesis. Alzheimers Dement (2017) 7:69–87. doi:10.1016/j.dadm.2017.01.005
65. Zhang F, Jiang L. Neuroinflammation in Alzheimer’s disease. Neuropsychiatr Dis Treat (2015) 11:243–56. doi:10.2147/NDT.S75546
66. Lee J-K, Tran T, Tansey MG. Neuroinflammation in Parkinson’s disease. J Neuroimmune Pharmacol (2009) 4:419–29. doi:10.1007/s11481-009-9176-0
67. Koyama A, O’Brien J, Weuve J, Blacker D, Metti AL, Yaffe K. The role of peripheral inflammatory markers in dementia and Alzheimer’s disease: a meta-analysis. J Gerontol A Biol Sci Med Sci (2013) 68:433–40. doi:10.1093/gerona/gls187
68. Lopez-Candales A, Hernández Burgos PM, Hernandez-Suarez DF, Harris D. Linking chronic inflammation with cardiovascular disease: from normal aging to the metabolic syndrome. J Nat Sci (2017) 3(4):e341.
69. Oishi Y, Manabe I. Macrophages in age-related chronic inflammatory diseases. NPJ Aging Mech Dis (2016) 2:16018. doi:10.1038/npjamd.2016.18
70. Cesari M, Penninx BWJH, Pahor M, Lauretani F, Corsi AM, Rhys Williams G, et al. Inflammatory markers and physical performance in older persons: the InCHIANTI study. J Gerontol A Biol Sci Med Sci (2004) 59:242–8. doi:10.1093/gerona/59.3.M242
71. Verghese J, Holtzer R, Oh-Park M, Derby CA, Lipton RB, Wang C. Inflammatory markers and gait speed decline in older adults. J Gerontol A Biol Sci Med Sci (2011) 66:1083–9. doi:10.1093/gerona/glr099
72. Solfrizzi V, Panza F, Colacicco AM, D’Introno A, Capurso C, Torres F, et al. Vascular risk factors, incidence of MCI, and rates of progression to dementia. Neurology (2004) 63:1882–91. doi:10.1212/01.WNL.0000144281.38555.E3
73. van Gijn J. Leukoaraiosis and vascular dementia. Neurology (1998) 51:S3–8. doi:10.1212/WNL.51.3_Suppl_3.S3
74. Domellöf ME, Elgh E, Forsgren L. The relation between cognition and motor dysfunction in drug-naive newly diagnosed patients with Parkinson’s disease. Mov Disord (2011) 26:2183–9. doi:10.1002/mds.23814
75. Vauzour D, Camprubi-Robles M, Miquel-Kergoat S, Andres-Lacueva C, Bánáti D, Barberger-Gateau P, et al. Nutrition for the ageing brain: towards evidence for an optimal diet. Ageing Res Rev (2017) 35:222–40. doi:10.1016/j.arr.2016.09.010
76. Dionyssiotis Y, Chhetri JK, Piotrowicz K, Gueye T, Sánchez E. Impact of nutrition for rehabilitation of older patients: report on the 1st EICA-ESPRM-EUGMS train the trainers course. Eur Geriatr Med (2017) 8:183–90. doi:10.1016/j.eurger.2016.11.011
77. Martone AM, Marzetti E, Calvani R, Picca A, Tosato M, Santoro L, et al. Exercise and protein intake: a synergistic approach against sarcopenia. Biomed Res Int (2017) 2017:2672435. doi:10.1155/2017/2672435
78. Lambert CP, Wright NR, Finck BN, Villareal DT. Exercise but not diet-induced weight loss decreases skeletal muscle inflammatory gene expression in frail obese elderly persons. J Appl Physiol (2008) 105:473–8. doi:10.1152/japplphysiol.00006.2008
79. Silva RB, Aldoradin-Cabeza H, Eslick GD, Phu S, Duque G. The effect of physical exercise on frail older persons: a systematic review. J Frailty Aging (2017) 6:91–6. doi:10.14283/jfa.2017.7
80. Koščak Tivadar B. Physical activity improves cognition: possible explanations. Biogerontology (2017) 18:477–83. doi:10.1007/s10522-017-9708-6
81. Wrigley S, Arafa D, Tropea D. Insulin-like growth factor 1: at the crossroads of brain development and aging. Front Cell Neurosci (2017) 11:14. doi:10.3389/fncel.2017.00014
82. Gill TM, Allore HG, Holford TR, Guo Z. Hospitalization, restricted activity, and the development of disability among older persons. JAMA (2004) 292:2115–24. doi:10.1001/jama.292.17.2115
83. Verghese J, Annweiler C, Ayers E, Barzilai N, Beauchet O, Bennett DA, et al. Motoric cognitive risk syndrome: multicountry prevalence and dementia risk. Neurology (2014) 83:718–26. doi:10.1212/WNL.0000000000000717
84. Verghese J, Ayers E, Barzilai N, Bennett DA, Buchman AS, Holtzer R, et al. Motoric cognitive risk syndrome: multicenter incidence study. Neurology (2014) 83:2278–84. doi:10.1212/WNL.0000000000001084
85. Allali G, Ayers EI, Verghese J. Motoric cognitive risk syndrome subtypes and cognitive profiles. J Gerontol A Biol Sci Med Sci (2016) 71:378–84. doi:10.1093/gerona/glv092
86. Doi T, Verghese J, Shimada H, Makizako H, Tsutsumimoto K, Hotta R, et al. Motoric cognitive risk syndrome: prevalence and risk factors in Japanese seniors. J Am Med Dir Assoc (2015) 16:1103.e21–5. doi:10.1016/j.jamda.2015.09.003
87. Sekhon H, Allali G, Launay CP, Chabot J, Beauchet O. The spectrum of pre-dementia stages: cognitive profile of motoric cognitive risk syndrome and relationship with mild cognitive impairment. Eur J Neurol (2017) 24:1047–54. doi:10.1111/ene.13331
88. Sosa AL, Albanese E, Stephan BCM, Dewey M, Acosta D, Ferri CP, et al. Prevalence, distribution, and impact of mild cognitive impairment in Latin America, China, and India: a 10/66 population-based study. PLoS Med (2012) 9:e1001170. doi:10.1371/journal.pmed.1001170
89. Kumai K, Meguro K, Kasai M, Nakamura K, Nakatsuka M. Neuroepidemiologic and neurobehavioral characteristics of motoric cognitive risk syndrome in an old-old population: the Kurihara project. Dement Geriatr Cogn Dis Extra (2016) 6:176–82. doi:10.1159/000445539
90. Falls_prevention7March.pdf. (2017). Available from: http://www.who.int/ageing/publications/Falls_prevention7March.pdf
91. Gill TM, Murphy TE, Gahbauer EA, Allore HG. Association of injurious falls with disability outcomes and nursing home admissions in community-living older persons. Am J Epidemiol (2013) 178:418–25. doi:10.1093/aje/kws554
92. Spaniolas K, Cheng JD, Gestring ML, Sangosanya A, Stassen NA, Bankey PE. Ground level falls are associated with significant mortality in elderly patients. J Trauma (2010) 69:821–5. doi:10.1097/TA.0b013e3181efc6c6
93. Lord SR, Clark RD, Webster IW. Physiological factors associated with falls in an elderly population. J Am Geriatr Soc (1991) 39:1194–200. doi:10.1111/j.1532-5415.1991.tb03574.x
Keywords: dementia, motoric cognitive risk, gait, cognition, subjective memory complaint, geriatric disorders
Citation: Chhetri JK, Chan P, Vellas B and Cesari M (2017) Motoric Cognitive Risk Syndrome: Predictor of Dementia and Age-Related Negative Outcomes. Front. Med. 4:166. doi: 10.3389/fmed.2017.00166
Received: 23 August 2017; Accepted: 20 September 2017;
Published: 25 October 2017
Edited by:
Emanuele Marzetti, Fondazione Policlinico Universitario Agostino Gemelli, ItalyReviewed by:
Giuseppe Pasqualetti, University of Pisa, ItalyAngelo Carfì, Università Cattolica del Sacro Cuore, Italy
Copyright: © 2017 Chhetri, Chan, Vellas and Cesari. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jagadish K. Chhetri, chhetri_jk@hotmail.com